CU20120057A7 - Composición vacunal contra el virus del dengue, kit y plásmido - Google Patents
Composición vacunal contra el virus del dengue, kit y plásmidoInfo
- Publication number
- CU20120057A7 CU20120057A7 CU2012000057A CU20120057A CU20120057A7 CU 20120057 A7 CU20120057 A7 CU 20120057A7 CU 2012000057 A CU2012000057 A CU 2012000057A CU 20120057 A CU20120057 A CU 20120057A CU 20120057 A7 CU20120057 A7 CU 20120057A7
- Authority
- CU
- Cuba
- Prior art keywords
- dengue virus
- dna vaccines
- plasid
- kit
- serotypes
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title abstract 6
- 108010041986 DNA Vaccines Proteins 0.000 abstract 3
- 229940021995 DNA vaccine Drugs 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101710204837 Envelope small membrane protein Proteins 0.000 abstract 1
- 101710088839 Replication initiation protein Proteins 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 229960001515 yellow fever vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un método para inducir la respuesta inmune contra el virus del dengue basado en vacunas de ADN y virus quiméricos 17D en inmunizaciones combinadas o coadministradas. rambién están dentro del objeo de la invención vacunas de ADN contra los cuatro serotipos del virus del dengue a partir de la construcción de distintos plásmidos recombinantes conteniendo el gen que codifica la proteína E, o sólamente la secuencia que corresponde al dominio III de esta proteína, a partir de cada serotipo viral del virus dengue (DENV1-4). La invención suministra aún, una composición vacunal consistiendo en (a) vacunas de ADN contra los cuatro serotipos del virus dengue, (b) virus quiméricos abarcando el virus vacunal de fiebre amarilla 17D modificado, y (c) un vehículo farmacéuticamente aceptable, está incluido en el objeto de protección.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
PCT/BR2010/000323 WO2011038473A1 (pt) | 2009-10-01 | 2010-08-01 | Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20120057A7 true CU20120057A7 (es) | 2013-01-30 |
CU24060B1 CU24060B1 (es) | 2014-12-26 |
Family
ID=43825448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20120057A CU24060B1 (es) | 2009-10-01 | 2012-04-02 | Composición vacunal contra el virus del dengue, kit y plásmido |
Country Status (10)
Country | Link |
---|---|
US (1) | US10357558B2 (es) |
EP (1) | EP2484376A4 (es) |
CN (1) | CN102711817B (es) |
BR (1) | BRPI0904020B8 (es) |
CL (1) | CL2012000783A1 (es) |
CO (1) | CO6541529A2 (es) |
CU (1) | CU24060B1 (es) |
EC (1) | ECSP12012131A (es) |
PE (2) | PE20121171A1 (es) |
WO (1) | WO2011038473A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20211814A1 (es) * | 2013-03-15 | 2021-09-14 | Takeda Vaccines Inc | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas |
BR112015031226A2 (pt) | 2013-06-21 | 2017-08-29 | Merck Sharp & Dohme | Composição de vacina, e, uso da composição de vacina |
ITRM20130458A1 (it) | 2013-08-05 | 2015-02-05 | Internat Ct For Genetic En Gineering And | Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope |
US10449243B2 (en) | 2014-12-22 | 2019-10-22 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
MX2021002586A (es) | 2018-09-05 | 2021-06-08 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administracion de esta. |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
US6881723B1 (en) * | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
US7476390B2 (en) * | 2002-02-26 | 2009-01-13 | Maxygen, Inc. | Flavivirus antigens |
US20080193477A1 (en) | 2005-08-10 | 2008-08-14 | Acambis Inc. | Vaccination Against Dengue Virus Infection |
ZA200802176B (en) * | 2005-08-10 | 2009-08-26 | Acambis Inc | Vaccination against dengue virus infection |
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
EP2086526B1 (en) | 2006-11-09 | 2014-07-23 | The United States Of America As Represented By The Secretary of the Navy | Induction of an immune response against Dengue virus using prime-boost approach |
CA2708668C (en) * | 2008-01-11 | 2019-03-05 | Vgx Pharmaceuticals, Llc | Vaccines against multiple subtypes of dengue virus |
-
2009
- 2009-10-01 BR BRPI0904020A patent/BRPI0904020B8/pt active IP Right Grant
-
2010
- 2010-08-01 PE PE2012000411A patent/PE20121171A1/es active IP Right Grant
- 2010-08-01 EP EP10819756.7A patent/EP2484376A4/en not_active Withdrawn
- 2010-08-01 CN CN201080052438.4A patent/CN102711817B/zh active Active
- 2010-08-01 WO PCT/BR2010/000323 patent/WO2011038473A1/pt active Application Filing
- 2010-08-01 US US13/499,697 patent/US10357558B2/en not_active Expired - Fee Related
- 2010-08-01 PE PE2016001214A patent/PE20161094A1/es unknown
-
2012
- 2012-03-29 CL CL2012000783A patent/CL2012000783A1/es unknown
- 2012-04-02 CU CU20120057A patent/CU24060B1/es active IP Right Grant
- 2012-04-26 CO CO12069004A patent/CO6541529A2/es unknown
- 2012-05-04 EC ECSP12012131 patent/ECSP12012131A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US10357558B2 (en) | 2019-07-23 |
CN102711817A (zh) | 2012-10-03 |
BRPI0904020A2 (pt) | 2011-06-14 |
CU24060B1 (es) | 2014-12-26 |
PE20161094A1 (es) | 2016-10-22 |
US20120251570A1 (en) | 2012-10-04 |
BRPI0904020B1 (pt) | 2019-11-12 |
CN102711817B (zh) | 2016-10-26 |
CL2012000783A1 (es) | 2013-03-22 |
ECSP12012131A (es) | 2013-02-28 |
PE20121171A1 (es) | 2012-08-30 |
EP2484376A1 (en) | 2012-08-08 |
CO6541529A2 (es) | 2012-10-16 |
BRPI0904020B8 (pt) | 2021-05-25 |
WO2011038473A8 (pt) | 2012-07-19 |
EP2484376A4 (en) | 2014-01-22 |
WO2011038473A1 (pt) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
CU20120057A7 (es) | Composición vacunal contra el virus del dengue, kit y plásmido | |
MX339241B (es) | Vacunas novedosas contra sub-tipos multiples de virus de influenza. | |
MX347997B (es) | Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle. | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
MX2009010549A (es) | Virus atenuados utiles para vacunas. | |
MX346862B (es) | Secuencias consenso de envoltura de vih y método para usar las mismas. | |
MX2010007461A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
NO20090194L (no) | Rekombinant viral vaksine | |
RU2015135890A (ru) | Композиция вакцины | |
JP2017526689A5 (es) | ||
MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
CO7461133A2 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
CO6700818A2 (es) | Vectores de parapoxvirus | |
AR067439A1 (es) | Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4 | |
CO6670515A2 (es) | Vectores de parapoxvirus | |
AR066823A1 (es) | Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp | |
Mooney et al. | Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses | |
CU24188B1 (es) | Composición vacunal contra el virus dengue | |
Guirakhoo | Replication-competent Viral Vectors | |
NZ602611A (en) | Replication-defective flavivirus vaccines and vaccine vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |